Australia's Nova Eye Medical climbs as US FDA clears medical device
** Shares of Nova Eye Medical Ltd EYE.AX climb as much as
26.8% to A$0.355, their highest since Jan 5
** Medical technology co says U.S. FDA cleared its
canaloplasty device iTrack™ Advance
** Says device is for sale to surgeons in the U.S. for
canal-based glaucoma surgery
** Stock posts its biggest intraday pct gain since March 21
** More than 2.5 mln shares change hands, 9 times the 30-day
average volume
(Reporting by Poonam Behura in Bengaluru)
((Poonam.Behura@thomsonreuters.com;))
Recent news on Nova Eye Medical
See all newsAustralia's Nova Eye Medical jumps on upbeat FY27 earnings guidance
Brief: Nova Eye Medical Reports FY26 Sales Of $23.7 Million
Australia's Nova Eye Medical soars on FY26 sales forecast upgrade
Brief: Nova Eye Medical Upgrades Fy26 Sales Guidance (Ex-China) To $22–23 Million
Australia's Nova Eye Medical rises on EU approval for glaucoma treatment